Teriparatide - Osteoporosis (Male and Juvenile)

You are here : Home > Formulary Search > Teriparatide - Osteoporosis (Male and Juvenile)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red

Formulations :

Subcutaneous injection (sc)

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

BNF SPC

NHSE

Restrictions / Comments :

Documentation

No records returned.

PAD Profile

ChemicalSubstance :

Teriparatide

Indication :

Osteoporosis (Male and Juvenile)

Group Name :

Keywords :

Brand Names Include :

Forsteo, Terrosa, Movymia, Sondelbay

Important Information :

RSFT only - commissioned as a Specialised Endocrinology Centre.

See separate entry for use in postmenopausal osteoporosis.

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Teriparatide is used to treat.

Osteoporosis

Other Drugs

Below are listed other drugs that are used to treat Osteoporosis (Male and Juvenile).

No records returned.

Committee Recommendations (1)

01 Apr 13 - Not Set

This drug / device falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care. Treatment should remain with the specialist (RED) hospital only drug. GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.

NOTE - Terrosa and Movymia are biosimilars. It is therefore necessary to prescribe teriparatide by brand to ensure that the patient receives the intended product.